Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 11c ; Offers Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.20), $0.11 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $42.8 million versus the consensus estimate of $36.21 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2024 revenue of $145-160 million, versus the consensus of $145.3 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Venu Holding enters $250 million at-the-market stock offering agreement